Nectin Therapeutics Licenses Novel Antibodies to Immunome

Provided By PR Newswire

Last update: Jul 25, 2024

– Exclusive worldwide license agreement for antibodies against undisclosed target

JERUSALEM, July 25, 2024 /PRNewswire/ -- Nectin Therapeutics, Ltd., a biotechnology company developing novel immunotherapies and antibody drug conjugates (ADC) to address tumor resistance, today announced a global, exclusive license agreement with Immunome Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies. Under the terms of the license, Immunome received exclusive rights to a panel of antibodies targeting an undisclosed target.